

**International Nutrition Research Center, Inc.
7900 Los Pinos Circle
Coral Gables, FI 33143**

**ProShape® Tablets
[(Master Amino Acid Pattern (MAP®))]
A safe and effective substitute for dietary proteins**

DESCRIPTION

ProShape® (MAP®) is a patented dietary proteins substitute, which provides a unique pattern of essential amino acids, in a highly purified, free, crystalline form. After oral ingestion, ProShape® is rapidly utilized. ProShape® does not require the aid of peptidases and therefore, it is absorbed, within 23 minutes, through the first 100 cm of functional small intestine. ProShape® does not provide any fecal residue. ProShape® is amphoteric. ProShape® is supplied in tablets of 1,000 mg for oral administration. Each tablet of ProShape®, in addition to the active ingredient MAP®, contains no inactive ingredients.

COMPOSITION

ProShape®, in a dose of 10 g, provides the following essential amino acids profile:


L-Leucine	1.964 g
L-Valine	1.657 g
L-Isoleucine	1.483 g
L-Lysine	1.429 g
L-Phenylalanine	1.289 g
L-Threonine	1.111 g
L-Methionine	0.699 g
L-Tryptophan	0.368 g

CLINICAL STUDIES

The results of a comparative, double-blind, triple crossover Net Nitrogen Utilization (NNU) clinical study have shown that the subjects, while taking MAP®, as a dietary proteins substitute, achieved a body's 99% NNU. This means that 99% of MAP's constituent amino acids followed the anabolic pathway, thus acting as precursor of body's protein synthesis. By comparison, dietary proteins only provide between 16 to 48% NNU. This fact evidences that MAP is more nutritious than dietary proteins. This has been confirmed by the fact that during the study, each subject body's nitrogen balance was maintained in equilibrium by taking MAP, as a sole and total substitute of dietary proteins, in a dosage of only 400 mg/kg/day, which provided less than 2 kcal/day (1g MAP= 0.04 Kcal). The study results have also shown that 1% of MAP's constituent amino acids followed the catabolic pathway, thus releasing only 1% of nitrogen catabolites and energy. By comparison dietary proteins release between 52% to 84% nitrogen catabolites and energy. This fact evidences that MAP is safer than dietary proteins, and that provides the lowest amount of energy in comparison to any dietary protein.


To illustrate: when a dietary protein is digested, it releases its constituent amino acids into the small intestine, where they are absorbed. Then, those amino acids can follow either the *anabolic pathway* or the *catabolic pathway* (Fig. I).

Figure I. Dietary Protein Metabolism




When dietary amino acids follow the *anabolic pathway*, they act as precursors for the body's protein synthesis, thus becoming the body's constituent proteins. Throughout the *anabolic pathway*, amino acids do not release any nitrogen catabolites or energy (Fig. II).

Figure II. The Protein Metabolism Anabolic Pathway



On the other hand, when dietary amino acids follow the *catabolic pathway*, they act only as a source of energy and not as precursors of body's proteins synthesis. Throughout the *catabolic pathway*, amino acids do release nitrogen catabolites and energy (Fig. III).

Figure III. The Protein Metabolism Catabolic Pathway



INDICATIONS AND USAGE

ProShape® is indicated as a safe and effective substitute for dietary proteins.

ProShape® Vs Dietary Proteins

Characteristics	ProShape®	Dietary Proteins
Net Nitrogen Utilization (NNU)	99%	16% - 48%
Nitrogen Catabolites	1%	52% - 84%
Body's Protein Synthesis	10g	Approx. 350g
Energy	0.04 Kcal/g	4 Kcal/g
Digestion	Approx. 23 minutes	3 – 5 hours
Contraindications	None	Renal Failure or Hepatic Failure
Adverse Reactions	None	Food Sensitivities
Shelf-Life	3 years	1 – 4 days
Refrigeration	Not needed	Needed
Volume	Approx. 30cc.	500 – 1000cc.

ADVERSE REACTIONS

No adverse reactions have been reported.

OVERDOSAGE

No adverse reactions have been reported.

DOSAGE AND ADMINISTRATION

ProShape® should be administered with food. ProShape® in a dosage of 400mg/kg/day has been shown to be adequate, as a sole and total substitute of dietary proteins, to maintain the body's nitrogen balance in equilibrium. To calculate the ProShape® dosage necessary to substitute dietary proteins, apply the following:

$$\text{ProShape® dosage} = (\text{Dietary Protein} \times 0.4) \text{ g}$$

For instance: to calculate the dosage of ProShape® necessary to substitute 10 g of dietary proteins, proceed as follows:

- a. ProShape® dosage = (Dietary Proteins x 0.4) g
- b. ProShape® dosage = (10 x 0.4) g
- c. ProShape® dosage = 4 g

Therefore, 4 g of ProShape® provide a body's protein synthesis equivalent to that provided by 10 g of high biological value dietary proteins.

SUPPLY INFORMATION

ProShape®, is available in bottles of 100 tablets of 1,000 mg, for oral administration.

Additional professional information on ProShape® is available through the International Nutritional Research Center, Inc.

Patent No. 5,132,113

COPYRIGHT © International Nutrition Research Center, Inc., 2003
All rights reserved

MAP® and (ProShape®) related scientific publications

1. M. Lucà-Moretti. Comparative study of subjects' Net Nitrogen Utilization (NNU) while receiving SON, a nutritional amino acid formula, or high biological value egg protein, or egg protein amino acid formula. *JIMHA*; 1:33-42,1992.
2. M. Lucà-Moretti. Comparative study of subjects' Net Nitrogen Utilization (NNU) while receiving SON, or egg protein or its protein amino acid formula. *Advances in Therapy*; 5:280-89,1992.M. Lucà-Moretti.
3. A Comparative, Double-blind, Triple Crossover Net Nitrogen Utilization Study Confirms the Discovery of the Master Amino Acid Pattern. *Annals of the Royal National Academy of Medicine of Spain, Madrid*; Vol. CXV: 397-416, 1998.
4. M. Lucà-Moretti. A Comparative, Double-blind, Triple Crossover Net Nitrogen Utilization Study Confirms the Discovery of the Master Amino Acid Pattern. *Annals of the Royal Academy of Medicine of Zaragoza. Zaragoza*; LXXII,1998.
5. D'Andrea G. Terapia delle obesità: Studio comparativo di 10 casi clinici trattati con MAP (Son Formula™) e terapia omotossicologica versus Orlistat (Xenical 120mg Roche). *La Medicina Biologica*; 3: 5-9, 2001.
6. Mariani M. M. Utilizzo del MAP (Master Amino Acid Pattern) nel Programma "Quattro D" nell'insufficienza venosa cronica. *La Medicina Biologica*; 3: 33-40, 2001.
7. Fidone B. Nutrizione biologica integrata con SON FORMULA™ in pazienti affetti da insufficienza cardiaca. *La Medicina Biologica*; 3: 53-66, 2001.
8. Bufalini L. Rieducazione nutrizionale e terapia omotossicologica in pazienti anoressiche amenorroiche. *La Medicina Biologica*; 3: 67-71, 2001.
9. M. Lucà-Moretti. The International Nutrition Research Center Overweight Management Program. *The Library of Congress, USA* 1999.
10. M. Lucà-Moretti, A. Grandi. The Malnutrition Treatment and Prevention Project. *JIMHA*; 2:20-26,1993.
11. M. Luca-Moretti. Programma di trattamento e prevenzione della malnutrizione. *La Medicina Biologica* ; 3: 35-38, 1999.
12. S. Costanzo. Nuova opportunita nella nutrizione delle popolazioni in situazioni di emergenza. *La Medicina Biologica* ; 3: 39-42, 1999.
13. Mariani E., Vender G., Arrigotti E., Ferrario M., Rovelli E. Variazione di alcuni parametri antropometrici e fisiologici in una marciatrice cinquantenne prima e dopo l'attraversamento in solitaria del deserto cinese. *La Medicina Biologica*; 3: 20-25, 1999.
14. Montilla C. Studio comparativo con e senza somministrazione di SON FORMULA® in soggetti affetti da anemia sideropenica sotto trattamento convenzionale. *La Medicina Biologica*; 3:2-7, 1999.
15. Fidone B. Rettocolite ulcerosa idiopatica: possibilita con MAP (SON Formula). *La Medicina Biologica*; 3:8-11, 1999.

16. Tamburlin N. Tratamento ambulatoriale di pazienti con insufficienza renale cronica, *La Medicina Biologica*; 3: 12-16, 1999.
17. Muratori G. Sovrappeso e patologia articolare: SON Formula come terapia dimagrante ed antalgica un'ipotesi di lavoro. *La Medicina Biologica*; 17-20, 1999.
18. Sanseverino E. R. Vantaggi dell'utilizzo del MAP in eta'geriatrica, *La Medicina Biologica*; 3: 17-19, 1999.
19. N. Tamburlin. L'importanza innovativa nell'uso del MAP per il controllo biologico del peso. *La Medicina Biologica*; 1:4-10,1997.
20. M. Luca-Moretti. Ensayo Comparativo sobre el MAP: el perfil ideal de aminoacidos esencioales para la nutricion humana, *International Journal for Biomedical Research and Therapy*; 4:9-14, 1997.
21. M. Luca Moretti, A.Grandi, E.Luca, E. Mariani, G.Vender, E.Arrigotti, M.Ferrario, E.Rovelli. Comparative Results Between Two Groups of Track and Field Athletes with or without the use of Master Amino Acids Pattern® as protein substitute. *Advances in Therapy*; 4:195-202, 2003.
22. M. Luca Moretti, A.Grandi, E.Luca, E. Mariani, G.Vender, E.Arrigotti, M.Ferrario, E.Rovelli. Results of taking Master Amino Acids Pattern® as a sole and total substitute of dietary proteins in an athlete during a desert crossing. *Advances in Therapy*; 4:203-210, 2003.
23. M. Luca Moretti, A.Grandi, E. Luca, G. Muratori, M.G. Nofroni, M.P. Mucci, P.Gambetta, R. Stimolo, P.Drago, G.Giudice, N.Tamburlin, M. Karbalay, C.Valente, G. Moras. Master Amino Acids Pattern® as sole and total substitute for dietary proteins during a weight loss diet to achieve the body's Nitrogen Balance equilibrium. *Advances in Therapy*; 5:270-281, 2003.
24. M. Luca Moretti, A.Grandi, E. Luca, G. Muratori, M.G. Nofroni, M.P. Mucci, P.Gambetta, R. Stimolo, P.Drago, G. Giudice, N. Tamburlin. Master Amino Acids Pattern® as substitute for dietary proteins during a weight loss diet to achieve the body's Nitrogen Balance equilibrium with essentially no calories. *Advances in Therapy*; 5:282-291, 2003.
25. M. Lucà-Moretti. Comparative study of subjects' Net Nitrogen Utilization (NNU) while receiving bovine milk or soybean flour with or without SON nutrification. *JIMHA*; 1:43-54,1992.
26. M. Lucà-Moretti. Comparative study of subjects' Net Nitrogen Utilization (NNU) while receiving bovine milk or soybean flour with or without SON nutrification. *Advances in Therapy*; 5:290-301,1992.